Abstract:Seven new compounds including four lanostane triterpenoids, lucidenic acids Q-S (1-3) and methyl ganoderate P (4), and three triterpene-farnesyl hydroquinone conjugates, ganolucinins A-C (5-7), one new natural product ganomycin J (8), and 73 known compounds (9-81) were isolated from fruiting bodies of Ganoderma lucidum. The structures of the compounds 1-8 were determined by spectroscopic methods. Bioactivities of compounds isolated were assayed against HMG-CoA reductase, aldose reductase, α-glucosidase, and PTP1B. Ganolucidic acid η (39), ganoderenic acid K (44), ganomycin J (8), and ganomycin B (61) showed strong inhibitory activity against HMG-CoA reductase with IC50 of 29.8, 16.5, 30.3 and 14.3μM, respectively. Lucidumol A (67) had relatively good effect against aldose reductase with IC50 of 19.1μM. Farnesyl hydroquinones ganomycin J (8), ganomycin B (61), ganomycin I (62), and triterpene-farnesyl hydroquinone conjugates ganoleuconin M (76) and ganoleuconin O (79) possessed good inhibitory activity against α-glucosidase with IC50 in the range of 7.8 to 21.5μM. This work provides chemical and biological evidence for the usage of extracts of G. lucidum as herbal medicine and food supplements for the control of hyperglycemic and hyperlipidemic symptoms.

Five Undescribed Meroterpenoids from Ganoderma Lucidum and Their Inhibitory Activities Against Renal Fibrosis

Meroterpenoids with a large conjugated system from Ganoderma lucidum and their inhibitory activities against renal fibrosis

Isolation and characterization of dihydropyran-ring containing meroterpenoids from Ganoderma lucidum and their inhibitory activity against renal fibrosis-related protein expression

Ganospirones A-G, seven undescribed spiro-meroterpenoids from Ganoderma lucidum and their biological activities

Anti-human immunodeficiency virus-1 protease activity of new lanostane-type triterpenoids from Ganoderma sinense.

Minor ergosteroids and a 19- nor labdane-type diterpenoid with anti-inflammatory effects from Ganoderma lucidum

Triterpenes and meroterpenes from Ganoderma lucidum with inhibitory activity against HMGs reductase, aldose reductase and α-glucosidase

New Lanostane-Type Triterpenoids from the Fruiting Body of Ganoderma Hainanense

Triterpenes from antler-shaped fruiting body of Ganoderma lucidum and their hepatoprotective activities

Triterpenoids and meroterpenoids with α-glucosidase inhibitory activities from the fruiting bodies of Ganoderma australe

(±)-Gancochlearols J − N, renoprotective meroterpenoids from Ganoderma cochlear

Terminal Cyclohexane-Type Meroterpenoids from the Fruiting Bodies of Ganoderma cochlear

Isolation and Bioactivity Evaluation of Terpenoids from the Medicinal FungusGanoderma Sinense

Cytotoxic lanostanoid triterpenes from Ganoderma lucidum.

Spiroganodermaines A−G from Ganoderma species and their activities against insulin resistance and renal fibrosis

Nor-triterpenoids from the fruiting bodies of Ganoderma lucidum and their inhibitory activity against FAAH

Meroterpenoids from the Fruiting Bodies of Ganoderma Ahmadii Steyaret and Their Protein Tyrosine Phosphatase 1B Inhibitory Activities

New ganoderic acids, bioactive triterpenoid metabolites from the mushroom Ganoderma lucidum

Triterpenoids with neurotrophic activity from Ganoderma lucidum.

Lanostanoids isolated from Ganoderma lucidum mycelium cultured by submerged fermentation

Lanostane-type triterpenoids from the mycelial mat of <i>Ganoderma lucidum</i> and their hepatoprotective activities